Core Viewpoint - Ralliant Corporation is facing scrutiny due to a significant non-cash goodwill impairment charge, which has led to a substantial decline in its stock price, prompting an investigation into potential violations of federal securities laws [2][3]. Financial Results - On February 4, 2026, Ralliant Corporation reported its fourth quarter and full year 2025 financial results, including a $1.4 billion non-cash goodwill impairment charge in the Test & Measurement segment, primarily attributed to revised expectations for the EA Elektro-Automatik business [2]. Stock Performance - Following the announcement of the impairment charge, Ralliant Corporation's stock price fell by $17.89 per share, representing a decline of approximately 31.8%, from a closing price of $56.28 on February 4, 2026, to $38.39 on February 5, 2026 [3].

Core Viewpoint - A securities class action lawsuit has been filed against Varonis Systems, Inc. for alleged material misstatements and omissions affecting investors who purchased or acquired Varonis common stock between February 4, 2025, and October 28, 2025 [1][6]. Group 1: Lawsuit Details - The lawsuit claims that Varonis was not adequately prepared to sustain its Annual Recurring Revenue (ARR) growth without maintaining a high rate of quarterly conversions [2]. - Defendants allegedly made misleading statements regarding the company's business operations and prospects, which lacked a reasonable basis [2]. - The lead plaintiff deadline for the lawsuit is set for March 9, 2026, allowing affected investors to seek representation [3][6]. Group 2: Legal Representation - Kessler Topaz Meltzer & Check, LLP is the law firm representing the class of investors and encourages those who suffered losses to contact them for more information [4][5]. - The firm has a strong reputation in securities-fraud class actions and has achieved significant recoveries in past litigations [5]. Group 3: Investor Information - Affected investors can choose to become lead plaintiffs or remain absent class members, with their ability to recover not impacted by this decision [3]. - The firm operates globally, with offices in Pennsylvania and California, and offers assistance to investors at no cost [6][7].

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors in uniQure N.V. following significant stock price decline due to FDA feedback on its gene therapy AMT-130 [1][4]. Group 1: Company Developments - On November 3, 2025, uniQure announced that the FDA indicated the data for its investigational gene therapy AMT-130 did not provide sufficient evidence to support its Biologics License Application (BLA) [2]. - The FDA no longer agrees that data from the Phase I/II studies of AMT-130 may be adequate for BLA submission, leading to uncertainty regarding the timing of the BLA submission [2]. Group 2: Market Reaction - Following the FDA's announcement, uniQure's stock price plummeted over 50%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [3].

Core Viewpoint - A securities class action lawsuit has been filed against Bitdeer Technologies Group for allegedly making false and misleading statements regarding its business operations and prospects during the class period from June 6, 2024, to November 10, 2025 [1]. Group 1: Allegations Against Bitdeer - The complaint claims that Bitdeer misrepresented issues with its SEAL04 chip design, which caused production delays [2]. - Bitdeer allegedly adopted a "dual-track approach" to create two independent designs to compensate for lost progress, while still assuring the public that production timelines were on track [2]. - As a result of these actions, the statements made by Bitdeer regarding its business and operations were deemed materially false and misleading [2]. Group 2: Lead Plaintiff Process - Investors in Bitdeer have until February 2, 2026, to seek appointment as a lead plaintiff representative for the class or may choose to remain absent [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is a prominent U.S. law firm specializing in securities-fraud class actions and global investor protection [4]. - The firm has a history of leading significant recoveries in securities litigation and has received multiple accolades for its work [4]. - KTMC operates globally with offices in Pennsylvania and California, representing both individual and institutional investors [4].

Core Viewpoint - A securities class action lawsuit has been filed against Bitdeer Technologies Group for allegedly making false and misleading statements regarding its business operations and prospects during the class period from June 6, 2024, to November 10, 2025 [1]. Group 1: Allegations Against Bitdeer - The complaint claims that Bitdeer misrepresented issues with the SEAL04 chip design, which caused production delays [2]. - Bitdeer allegedly adopted a "dual-track approach" to create two independent designs to compensate for lost progress, while still assuring the public that production timelines were on track [2]. - As a result of these actions, the statements made by Bitdeer regarding its business and operations were deemed materially false and misleading [2]. Group 2: Lead Plaintiff Process - Investors in Bitdeer have until February 2, 2026, to seek appointment as a lead plaintiff representative for the class [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is a prominent law firm specializing in securities-fraud class actions and represents both individual and institutional investors [4]. - The firm has achieved significant recoveries in securities litigation and has received numerous accolades for its work in this field [4].

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified class period [1]. Group 1: Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems [3]. - The design changes reportedly rendered the G6 and G7 devices less reliable, posing health risks to users relying on accurate glucose readings [3]. - DexCom is accused of overstating the enhancements and reliability of the G7 device while downplaying the severity of issues related to adulterated devices [3]. - The company allegedly faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these issues [3]. Group 2: Legal Process and Representation - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiffs in the class action [4]. - A lead plaintiff represents the interests of all class members and selects counsel to direct the litigation [4]. - Investors can choose to remain absent from the proceedings without affecting their ability to share in any recovery [4].

Core Viewpoint - A securities class action lawsuit has been filed against StubHub Holdings, Inc. related to its September 2025 initial public offering, alleging misleading statements in the Offering Documents [1][2]. Group 1: Allegations Against StubHub - The lawsuit claims that StubHub made false and/or misleading statements regarding changes in the timing of payments to vendors [2]. - It is alleged that these changes had a significant adverse impact on StubHub's free cash flow, making previous reports materially misleading [2]. - The complaint asserts that the positive statements made by StubHub about its business and operations were materially false and lacked a reasonable basis [2]. Group 2: Lead Plaintiff Process - Investors in StubHub have until January 23, 2026, to seek appointment as a lead plaintiff representative of the class [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is a prominent U.S. law firm specializing in securities-fraud class actions and investor protection [4]. - The firm has a history of leading significant recoveries in securities litigation and has received numerous accolades in the legal field [4].